Marker Therapeutics (NASDAQ:MRKR) Announces Quarterly Earnings Results

Marker Therapeutics (NASDAQ:MRKR) announced its earnings results on Friday. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.16, Zacks reports. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 73.29%.

Marker Therapeutics Stock Up 2.7%

Shares of MRKR stock traded up $0.03 on Friday, hitting $1.14. 45,559 shares of the stock were exchanged, compared to its average volume of 46,148. Marker Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $2.46. The business has a 50-day moving average of $1.33 and a 200 day moving average of $1.43.

Analysts Set New Price Targets

Several research analysts have recently weighed in on MRKR shares. Weiss Ratings cut shares of Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 6th. HC Wainwright restated a “buy” rating on shares of Marker Therapeutics in a report on Wednesday, May 20th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Marker Therapeutics currently has an average rating of “Hold” and an average price target of $10.00.

Institutional Investors Weigh In On Marker Therapeutics

Institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in Marker Therapeutics during the 3rd quarter worth approximately $25,000. Two Sigma Investments LP acquired a new stake in shares of Marker Therapeutics in the third quarter valued at approximately $33,000. Jane Street Group LLC acquired a new stake in shares of Marker Therapeutics in the second quarter valued at approximately $33,000. XTX Topco Ltd lifted its position in shares of Marker Therapeutics by 166.6% in the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after purchasing an additional 36,269 shares in the last quarter. Finally, LPL Financial LLC lifted its position in shares of Marker Therapeutics by 41.7% in the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after purchasing an additional 24,500 shares in the last quarter. Institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.